A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
PHASE1CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
Not specified
Study Completion Date
May 31, 1997
Conditions
HIV InfectionsHIV Seronegativity
Interventions
BIOLOGICAL
gp160 Vaccine (Immuno-AG)
Trial Locations (2)
63104
St. Louis Univ. School of Medicine AVEG, St Louis
98144
UW - Seattle AVEG, Seattle
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00001043 - A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules | Biotech Hunter | Biotech Hunter